TW202221022A - 用於治療阿茲海默症之ｔａｕ疫苗 - Google Patents

用於治療阿茲海默症之ｔａｕ疫苗 Download PDF

Info

Publication number
TW202221022A
TW202221022A TW110118155A TW110118155A TW202221022A TW 202221022 A TW202221022 A TW 202221022A TW 110118155 A TW110118155 A TW 110118155A TW 110118155 A TW110118155 A TW 110118155A TW 202221022 A TW202221022 A TW 202221022A
Authority
TW
Taiwan
Prior art keywords
seq
peptide
amino acid
acid sequence
tau
Prior art date
Application number
TW110118155A
Other languages
English (en)
Chinese (zh)
Inventor
羅賓 巴柏
吉因 金尼
瓦格奈 薩果
塔爾洛強 Ｓ 尼杰
Original Assignee
愛爾蘭商普羅佘納生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商普羅佘納生物科技有限公司 filed Critical 愛爾蘭商普羅佘納生物科技有限公司
Publication of TW202221022A publication Critical patent/TW202221022A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW110118155A 2020-08-07 2021-05-19 用於治療阿茲海默症之ｔａｕ疫苗 TW202221022A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062971P 2020-08-07 2020-08-07
US63/062,971 2020-08-07

Publications (1)

Publication Number Publication Date
TW202221022A true TW202221022A (zh) 2022-06-01

Family

ID=80118379

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110118155A TW202221022A (zh) 2020-08-07 2021-05-19 用於治療阿茲海默症之ｔａｕ疫苗

Country Status (12)

Country Link
US (1) US20230302127A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192583A4 (cg-RX-API-DMAC10.html)
JP (2) JP2023536746A (cg-RX-API-DMAC10.html)
KR (1) KR20230080398A (cg-RX-API-DMAC10.html)
CN (1) CN117751132A (cg-RX-API-DMAC10.html)
AR (1) AR122129A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021321206A1 (cg-RX-API-DMAC10.html)
CA (1) CA3188458A1 (cg-RX-API-DMAC10.html)
IL (1) IL300346A (cg-RX-API-DMAC10.html)
MX (1) MX2023001501A (cg-RX-API-DMAC10.html)
TW (1) TW202221022A (cg-RX-API-DMAC10.html)
WO (1) WO2022031342A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894659A (zh) * 2022-10-19 2023-04-04 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
WO2015098963A1 (ja) * 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
WO2015165961A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
SG11201910066QA (en) * 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
JP2020536946A (ja) * 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
TWI859197B (zh) * 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894659A (zh) * 2022-10-19 2023-04-04 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Also Published As

Publication number Publication date
WO2022031342A1 (en) 2022-02-10
KR20230080398A (ko) 2023-06-07
EP4192583A1 (en) 2023-06-14
MX2023001501A (es) 2023-03-08
EP4192583A4 (en) 2025-02-12
CN117751132A (zh) 2024-03-22
JP2026120788A (ja) 2026-07-22
AU2021321206A1 (en) 2023-03-09
US20230302127A1 (en) 2023-09-28
JP2023536746A (ja) 2023-08-29
IL300346A (en) 2023-04-01
AR122129A1 (es) 2022-08-17
CA3188458A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
US11945849B2 (en) Multi-epitope vaccine for the treatment of Alzheimer's disease
US20250186567A1 (en) Multiepitope vaccine for the treatment of alzheimer's disease
TW202212348A (zh) 用於治療阿茲海默症之β類澱粉蛋白疫苗
US20230302127A1 (en) Tau vaccine for the treatment of alzheimer's disease
US20230355729A1 (en) Multiepitope vaccine for the treatment of alzheimer's disease
TW202227465A (zh) 治療突觸核蛋白病症之α－突觸核蛋白疫苗